Read more on P-BCMA-ALLO1 “showing promise in multiple myeloma” as featured in GEN | View our supporting IMS data here

Inclusion on list recognizes Poseida for employee sentiment and satisfaction SAN DIEGO , Oct. 3, 2024 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with